Treatment with an intramuscular hepatocyte growth factor reduced healing time and promoted full ulcer healing compared with placebo in patients with peripheral artery disease.

For patients with chronic, limb-threatening ischemia due to atherosclerosis that affects the arteries below the knee, a revascularization strategy using endovascular treatment as the first option was ...

Critical Limb Ischemia companies are Boston Scientific Corporation, AnGes, Inc., Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, Medtronic Endovascular, Ixaka Ltd ...

In patients with critical limb ischemia (CLI) and no good therapeutic options, treatment with autologous stem cells appears safe and may help stave off amputation, according to data from a small ...

According to Coherent Market Insights (CMI), the global critical limb ischemia market size is projected to expand at a CAGR of 8.8%, growing from USD 5.55 Bn in 2025 to USD 10.02 Bn by 2032. Based on ...

A study documents poor outcomes among hospitalized patients with kidney failure and critical limb ischemia who did not receive dialysis. Critical limb ischemia is common among patients with end-stage ...

Treatments that restore blood flow to the lower limbs of people with a serious circulation condition may be cheaper and associated with longer survival, than amputation according to new research in ...

New research has shown human neural stem cells could improve blood flow in critical limb ischemia through the growth of new vessels. New research has shown human neural stem cells could improve blood ...

PARIS--(BUSINESS WIRE)--LimFlow SA, developer of endovascular technology transforming the treatment of critical limb ischemia (CLI), today announced that it received the CE Mark (Conformité Européenne ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a novel bioresorbable scaffold for the treatment of chronic limb-threatening ischemia. The ...